July 28, 2025
Felicia Timmermann, OD, MS, FAAO, Senior Manager of Myopia Management
ROCHESTER, N.Y. — For the fifth consecutive year, CooperVision has launched a nationwide myopia awareness campaign. The national media tour kicked off on July 24, and the direct-to-consumer initiative addressed the condition of myopia and its rising prevalence.
In a series of live and recorded interviews that aired across major broadcast and radio outlets nationally, Felicia Timmermann, OD, MS, FAAO, Senior Manager of Myopia Management, explained how simple lifestyle changes, such as increased screen time and less outdoor play, are accelerating the myopia epidemic. She emphasized the importance of early intervention, offering parents clear and actionable steps to help protect their children’s vision, which include combining daily outdoor activity with clinically proven interventions like MiSight 1 day* contact lenses, the first and only FDA-approved* soft contact lens proven to slow the progression of myopia in children aged 8-12 at the initiation of treatment.†1
Highlights from this year’s campaign included:
- 33 total interviews; 26 television, seven radio
- Coverage across 21 U.S. markets, including San Francisco, New York and Washington, D.C.
For the fifth year in a row, CooperVision is harnessing the power of national media to spotlight pediatric myopia—demonstrating leadership in raising public awareness, advancing education and expanding access to treatment options.
For more information, visit www.MiSight.com.
References
* Indications for use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with < 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
†Compared to a single vision one-day lens over a three-year period.
- Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
